Reported about 7 hours ago
Johnson & Johnson exceeded quarterly sales and profit estimates in Q4 2024, primarily due to robust cancer drug sales, particularly with its leading treatment Darzalex, which saw a 20.9% increase. The company reported revenues of $22.52 billion and anticipates 2025 sales between $90.9 billion and $91.7 billion. Despite a negative currency impact affecting profits, J&J continues its acquisition strategy, notably the recent $14.6 billion purchase of Intra-Cellular. The company's innovative medicine and medtech divisions also showed growth, although sales of its major psoriasis treatment Stelara declined.
Source: YAHOO